Dergiler / Journal of Medicine and Palliative Care / 2026 / Volume: 7 Issue: 5

The prognostic value of the Systemic Immune-Inflammation Index at diagnosis in small cell lung cancer

Sayfa
—
Yayın Tarihi
2026-10-25
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: A higher diagnostic SII was associated with worse survival in SCLC but behaved as a modest marker, with no statistically significant superiority over the NLR or PNI demonstrated in this limited cohort, with its independent value limited by disease stage.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aims: The Systemic Immune-Inflammation Index (SII) is a blood-based marker of systemic inflammation with prognostic value in several cancers, but its role in small cell lung cancer (SCLC) relative to simpler indices remains unclear.
📊
Temel Bulgular & Veri:We evaluated the association between the diagnostic SII and overall survival (OS) in SCLC and compared its prognostic performance with the neutrophil-to-lymphocyte ratio (NLR) and Prognostic Nutritional Index (PNI).
💡
Sonuç & Katkı:Conclusion: A higher diagnostic SII was associated with worse survival in SCLC but behaved as a modest marker, with no statistically significant superiority over the NLR or PNI demonstrated in this limited cohort, with its independent value limited by disease stage.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Small cell lung carcinoma · prognosis · inflammation

Abstract

Aims: The Systemic Immune-Inflammation Index (SII) is a blood-based marker of systemic inflammation with prognostic value in several cancers, but its role in small cell lung cancer (SCLC) relative to simpler indices remains unclear. We evaluated the association between the diagnostic SII and overall survival (OS) in SCLC and compared its prognostic performance with the neutrophil-to-lymphocyte ratio (NLR) and Prognostic Nutritional Index (PNI). Methods: In this single-centre retrospective cohort, 100 patients with histologically confirmed SCLC were analysed. The SII, NLR, and PNI were calculated at diagnosis. Discrimination was assessed using Harrell's concordance index, and patients were dichotomized at the median SII for the survival analyses. Survival was analysed using Kaplan-Meier, log-rank, and Cox regression, with the primary multivariable model stratified by stage. Results: The median age was 69 years; 70% had extensive-stage disease, and 89% died over a median observed time (from diagnosis to death or last contact) of 9.9 months. The SII showed modest discrimination (Harrell C-index 0.564). In the primary multivariable analysis stratified by disease stage, the SII was not independently associated with OS (adjusted HR 1.39, 95% CI 0.90-2.14, p=0.139), and it did not add significant value to a clinical model containing age, gender, and stage (ΔC-index 0.008, 95% CI -0.025 to 0.050). The SII, NLR, and PNI showed comparable and modest prognostic performance (C-index 0.56-0.60), with no significant differences. Conclusion: A higher diagnostic SII was associated with worse survival in SCLC but behaved as a modest marker, with no statistically significant superiority over the NLR or PNI demonstrated in this limited cohort, with its independent value limited by disease stage.

🔖

Bu Makaleye Atıf Yap

Alemdar, M. S., Mutlu, H. (2026). The prognostic value of the Systemic Immune-Inflammation Index at diagnosis in small cell lung cancer. Journal of Medicine and Palliative Care, Volume: 7 Issue: 5. https://ajindex.com/articles/1668080

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (20)

  1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
  2. Zhou Y, Dai M, Zhang Z. Prognostic significance of the Systemic Immune-Inflammation Index (SII) in patients with small cell lung cancer: a meta-analysis. Front Oncol. 2022;12:814727. doi:10.3389/fonc.2022.814727
  3. Peker P, Geçgel A, Özkan O, et al. Systemic Immune-Inflammation Index as a prognostic marker in gastric and gastroesophageal junction cancers receiving perioperative FLOT therapy. Medicina (Kaunas). 2025;61(9):1614. doi:10.3390/medicina61091614
  4. Shimizu K, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M. Preoperative neutrophil/lymphocyte ratio and Prognostic Nutritional Index predict survival in patients with non-small cell lung cancer. World J Surg Oncol. 2015;13:291. doi:10.1186/s12957-015-0710-7
  5. Hu B, Yang XR, Xu Y, et al. Systemic Immune-Inflammation Index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212-6222. doi:10.1158/1078-0432.Ccr-14-0442
  6. Jomrich G, Paireder M, Kristo I, et al. High Systemic Immune-Inflammation Index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma. Ann Surg. 2021;273(3):532-541. doi:10.1097/sla.0000000000003370
  7. Onodera T, Goseki N, Kosaki G. Prognostic Nutritional Index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85(9):1001-1005.
  8. Zhou L, Zhang Z, Tian Y, Li Z, Liu Z, Zhu S. The critical role of platelet in cancer progression and metastasis. Eur J Med Res. 2023;28(1):385. doi:10.1186/s40001-023-01342-w
  9. Liao K, Zhang X, Liu J, et al. The role of platelets in the regulation of tumor growth and metastasis: the mechanisms and targeted therapy. MedComm (2020). 2023;4(5):e350. doi:10.1002/mco2.350
  10. Yang N, Gong J, Ge C, et al. Platelet–neutrophil cooperation in cancer: mechanisms of metastatic niche formation and implications for prognostic stratification and therapy. Cell Oncol (Dordr). 2026;49(4):95. doi:10.1007/s13402-026-01178-6
  11. Qiu Y, Zhang Z, Chen Y. Prognostic value of pretreatment Systemic Immune-Inflammation Index in gastric cancer: a meta-analysis. Front Oncol. 2021;11:537140. doi:10.3389/fonc.2021.537140
  12. Yang X, Wu C. Systemic Immune Inflammation Index and gastric cancer prognosis: a systematic review and meta analysis. Exp Ther Med. 2024;27(3):122. doi:10.3892/etm.2024.12410
  13. Li X, Zhang S, Lu J, Li C, Li N. The prognostic value of Systemic Immune-Inflammation Index in surgical esophageal cancer patients: an updated meta-analysis. Front Surg. 2022;9:922595. doi:10.3389/fsurg.2022.922595
  14. Tan Y, Hu B, Li Q, Cao W. Prognostic value and clinicopathological significance of pre-and post-treatment Systemic Immune-Inflammation Index in colorectal cancer patients: a meta-analysis. World J Surg Oncol. 2025;23(1):11. doi:10.1186/s12957-025-03662-z
  15. Fu F, Deng C, Wen Z, et al. Systemic Immune-Inflammation Index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer. Transl Lung Cancer Res. 2021;10(7):3144-3154. doi:10.21037/tlcr-21-267
  16. Zhang Z, Zhao Y, Wen J, Wang Y, Li J. Impact of Systemic Immune-Inflammation Index and its evaluation of optimal threshold in patients with limited-stage small cell lung cancer: a retrospective study based on 572 cases. Transl Cancer Res. 2025;14(1):371-382. doi:10.21037/tcr-24-1266
  17. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86(11):829-835. doi:10.1093/jnci/86.11.829
  18. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25(1):127-141. doi:10.1002/sim.2331
  19. Lu Y, Jiang J, Ren C. The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: A meta-analysis. PLoS One. 2020;15(4):e0230979. doi:10.1371/journal.pone.0230979
  20. Wang B, Zhang J, Shi Y, Wang Y. Clinical significance of the combined Systemic Immune-Inflammatory Index and Prognostic Nutritional Index in predicting the prognosis of patients with extensive-stage small-cell lung cancer receiving immune-combination chemotherapy. BMC Cancer. 2024;24(1):1574. doi:10.1186/s12885-024-13343-x